Defensins and sepsis

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Xie, Guo Hao ^a   Chen, Qi Xing ^a   Cheng, Bao Li ^a   Fang, Xiang Ming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEFENSIN; INTERLEUKIN 1BETA;

ANTIMICROBIAL ACTIVITY; DISEASE PREDISPOSITION; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PATHOGENESIS; REVIEW; SEPSIS; ADAPTIVE IMMUNITY; DENDRITIC CELL; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; NEUTROPHIL; PATHOLOGY; PHAGOCYTOSIS; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; DEFENSINS; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1BETA; NEUTROPHILS; PHAGOCYTOSIS; SEPSIS; T-LYMPHOCYTES;

EID: 84907416275     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/180109     Document Type: Review

References (50)

1. R. S. Hotchkiss and I. E. Karl, "The pathophysiology and treatment of sepsis," The New England Journal of Medicine, vol. 348, no. 2, pp. 138-150, 2003.
2. J. A. Russell, "Management of sepsis," The New England Journal of Medicine, vol. 355, no. 16, pp. 1699-1713, 2006.
3. J. Cohen, "Theimmunopathogenesis of sepsis," Nature, vol. 420, no. 6917, pp. 885-891, 2002.
4. G. S. Martin, D. M. Mannino, S. Eaton, and M. Moss, "The epidemiology of sepsis in the United States from 1979 through 2000," New England Journal of Medicine, vol. 348, no. 16, pp. 1546-1554, 2003.
5. B. Cheng, G. Xie, S. Yao et al., "Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China," Critical Care Medicine, vol. 35, no. 11, pp. 2538-2546, 2007.
6. D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky, "Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care," Critical Care Medicine, vol. 29,no. 7, pp. 1303-1310, 2001.
7. F. B. Mayr, S. Yende, and D. C. Angus, "Epidemiology of severe sepsis," Virulence, vol. 5, no. 1, pp. 4-11, 2014.
8. R. P. Wenzel, "Treating sepsis," The New England Journal of Medicine, vol. 347, no. 13, pp. 966-967, 2002.
9. R. S. Hotchkiss, G. Monneret, and D. Payen, "Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach," The Lancet Infectious Diseases, vol. 13, no. 3, pp. 260-268, 2013.
10. Y. Yamaguchi and Y. Ouchi, "Antimicrobial peptide defensin identification of novel isoforms and the characterization of their physiological roles and their significance in the pathogenesis of diseases," Proceedings of the Japan Academy B, Physical and Biological Sciences, vol. 88, no. 4, pp. 152-166, 2012.
11. G. Wang, "Human antimicrobial peptides and proteins," Pharmaceuticals, vol. 7, no. 5, pp. 545-594, 2014.
12. M. E. Selsted and A. J. Ouellette, "Mammalian defensins in the antimicrobial immune response," Nature Immunology, vol. 6, no. 6, pp. 551-557, 2005.
13. J. J. Schneider, A. Unholzer, M. Schaller et al., "Human defensins," Journal of Molecular Medicine, vol. 83, no. 8, pp. 587-595, 2005.
14. Y. Tang, J. Yuan, G. Ösapay et al., "A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated α-defensins," Science, vol. 286, no. 5439, pp. 498-502, 1999.
15. P. Tongaonkar, P. Tran, K. Roberts et al., "Rhesus macaque θ-defensin isoforms: expression, antimicrobial activities, and demonstration of a prominent role in neutrophil granule microbicidal activities," Journal of Leukocyte Biology, vol. 89,no. 2, pp. 283-290, 2011.
16. C. L. Wohlford-Lenane, D. K. Meyerholz, S. Perlman et al., "Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease," Journal of Virology, vol. 83, no. 21, pp. 11385-11390, 2009.
17. K. M. Varney, A.M. Bonvin, and M. Pazgier, "Turning defensin mimetics novel antibiotics targeting lipid II," PLOS Pathogens, vol. 9, no. 11, Article ID e1003732, 2013.
18. T. Ganz, "Defensins: antimicrobial peptides of innate immunity," Nature Reviews Immunology, vol. 3, no. 9, pp. 710-720, 2003.
19. J.Harder, J. Bartels, E. Christophers, and J. Schröder, "Isolation and characterization of human β-defensin-3, a novel human inducible peptide antibiotic," Journal of Biological Chemistry, vol. 276, no. 8, pp. 5707-5713, 2001.
20. B. O. Schroeder, Z. Wu, S. Nuding et al., "Reduction of disulphide bonds unmasks potent antimicrobial activity of human β 2-defensin 1," Nature, vol. 469, no. 7330, pp. 419-423, 2011.
21. S. U. Jaeger, B. O. Schroeder, U. Meyer-Hoffert et al., "Cell-mediated reduction of human β-defensin 1: major role for mucosal thioredoxin," Mucosal Immunology, vol. 6, no. 6, pp. 1179-1190, 2013.
22. Y. Lai and R. L. Gallo, "AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense," Trends in Immunology, vol. 30, no. 3, pp. 131-141, 2009.
23. D. Yang, A. Biragyn, D. M. Hoover, J. Lubkowski, and J. J. Oppenheim, "Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense," Annual Review of Immunology, vol. 22, pp. 181-215, 2004.
24. S. Schaller-Bals, A. Schulze, and R. Bals, "Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection," The American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 7, pp. 992-995, 2002.
25. H. Mukae, H. Ishimoto, S. Yanagi et al., "Elevated BALF concentrations of α- and α-defensins in patients with pulmonary alveolar proteinosis," Respiratory Medicine, vol. 101, no. 4, pp. 715-721, 2007.
26. T. D. Starner, B. Agerberth, G. H. Gudmundsson, and P. B. McCray Jr., "Expression and activity of β-defensins and LL-37 in the developing human lung," Journal of Immunology, vol. 174, no. 3, pp. 1608-1615, 2005.
27. M. Book, Q. Chen, L. E. Lehmann et al., "Inducibility of the endogenous antibiotic peptide β-defensin 2 is impaired in patients with severe sepsis," Critical Care, vol. 11, article R19, 2007.
28. S. M. Milner and M. R. Ortega, "Reduced antimicrobial peptide expression in human burn wounds," Burns, vol. 25, no. 5, pp. 411-413, 1999.
29. K. Fellermann, D. E. Stange, E. Schaeffeler et al., "Achromosome 8 gene-cluster polymorphism with low human geta-defensin 2 gene copy number predisposes to Crohn disease of the colon," The American Journal of Human Genetics, vol. 79, no. 3, pp. 439-448, 2006.
30. A. Fahlgren, S. Hammarström, A˚. Danielsson, and M.-L. Hammarström, "β-defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis," Clinical and Experimental Immunology, vol. 137, no. 2, pp. 379-385, 2004.
31. Q. Shu, Z. Shi, Z. Zhao et al., "Protection against Pseudomonas aeruginosa pneumonia and sepsis-induced lung injury by overexpression of β-defensin-2 in rats," Shock, vol. 26,no. 4, pp. 365-371, 2006.
32. H. H. Wang, Q. Shu, and Z. Shi, "The protective effect of beta-defensin 2 in acute lung injury induced by respiratory Pseudomonas aeruginosa infection in rats," Chinese Journal of Anesthesiology, vol. 25, pp. 762-764, 2005.
33. J. M. Bao, H. P. Yao, Z. Chen et al., "The effect of pretreatment of recombinant beta-defensin 2 on the ICAM-1 expression in lung of rats with acute lung injury," Chinese Journal of Anesthesiology, vol. 25, pp. 702-703, 2005.
34. P. Olbrich, A. Pavón, M. L. Rosso et al., "Association of human beta-defensin-2 serum levels and sepsis in preterm neonates," Pediatric Critical Care Medicine, vol. 14, no. 8, pp. 796-800, 2013.
35. J. B. Schaal, D. Tran, P. Tran et al., "Rhesus macaque theta defensins suppress inflammatory cytokines and enhance survival in mouse models of bacteremic sepsis," PLoS ONE, vol. 7, no. 12, Article ID e51337, 2012.
36. Q. Chen, Y. Jin, K. Zhang et al., "Alarmin HNP-1 promotes pyroptosis and IL-1β release through different roles of NLRP3 inflammasome via P2X7 in LPS-primed macrophages," Innate Immunity, vol. 20, no. 3, pp. 290-300, 2014.
37. K. Bdeir, A. A. Higazi, I. Kulikovskaya et al., "Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier," American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 9, pp. 935-946, 2010.
38. I. Matsushita, K. Hasegawa, K. Nakata, K. Yasuda, K. Tokunaga, and N. Keicho, "Genetic variants of human β-defensin-1 and chronic obstructive pulmonary disease," Biochemical and Biophysical Research Communications, vol. 291, no. 1, pp. 17-22, 2002.
39. H. Levy, B. A. Raby, S. Lake et al., "Association of defensin beta-1 gene polymorphism with asthma," Journal of Allergy and Clinical Immunology, vol. 115, no. 2, pp. 252-258, 2005.
40. L. Braida, M. Boniotto, A. Pontillo, P. A. Tovo, A. Amoroso, and S. Crovella, "A single-nucleotide polymorphism in the human beta-defensin 1 gene as associated with HIV-1 infection in Italian children," AIDS, vol. 18, no. 11, pp. 1598-1600, 2004.
41. R. J. Jurevic, M. Bai, R. B. Chadwick, T. C. White, and B. A. Dale, "Single-nucleotide polymorphisms (SNPs) in human β-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls," Journal of Clinical Microbiology, vol. 41, no. 1, pp. 90-96, 2003.
42. A. M. Wallace, J. He, K. M. Burkett et al., "Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study," Respiratory Research, vol. 7, article 76, 2006.
43. M. T. Lin and T. E. Albertson, "Genomic polymorphisms in sepsis," Critical Care Medicine, vol. 32, no. 2, pp. 569-579, 2004.
44. Q. X.Chen,C. Lv, L. X.Huang et al., "Genomic variations within DEFB1 are associated with the susceptibility to and the fatal outcome of severe sepsis in Chinese Han population," Genes and Immunity, vol. 8, no. 5, pp. 439-443, 2007.
45. A. G. Nackley, S. A. Shabalina, I. E. Tchivileva et al., "Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure," Science, vol. 314, no. 5807, pp. 1930-1933, 2006.
46. E. J. Hollox, J. A. L. Armour, and J. C. K. Barber, "Extensive normal copy number variation of a β-defensin antimicrobialgene cluster," The American Journal of Human Genetics, vol. 73, no. 3, pp. 591-600, 2003.
47. P.M.R. Aldred, E. J. Hollox, and J. A. L. Armour, "Copy number polymorphism and expression level variation of the human α- defensin genes DEFA1 and DEFA3," Human Molecular Genetics, vol. 14, no. 14, pp. 2045-2052, 2005.
48. Q. Chen, M. Book, X. Fang, A. Hoeft, and F. Stuber, "Screening of copy number polymorphisms in human β-defensin genes usingmodified real-time quantitative PCR," Journal of Immunological Methods, vol. 308, no. 1-2, pp. 231-240, 2006.
49. Q. Chen, M. Hakimi, S. Wu et al., "Increased genomic copy number of DEFA1/DEFA3 is associated with susceptibility to severe sepsis in Chinese han population," Anesthesiology, vol. 112, no. 6, pp. 1428-1434, 2010.
50. K. Taylor, D. J. Clarke, B. McCullough et al., "Analysis and separation of residues important for the chemoattractant and antimicrobial activities of beta-defensin 3," The Journal of Biological Chemistry, vol. 283, no. 11, pp. 6631-6639, 2008.